Search - tctmd.com

Displaying 201 - 220 of 909

Sort: Relevancy | Date

Chinese Registry Supports Prolonged DAPT Following PCI for ACS

News Conference News SCAI 2021

Chinese Registry Supports Prolonged DAPT Following PCI for ACS

Yael L. Maxwell

May 03, 2021

Better Success With Next-Generation Robotic PCI: PRECISION GRX

News Conference News SCAI 2021

Better Success With Next-Generation Robotic PCI: PRECISION GRX

April 30, 2021

Adjustable Stent Retriever Performs Well in IDE Trial

News Conference News ISC 2021

Adjustable Stent Retriever Performs Well in IDE Trial

March 24, 2021

Polymer-Free Stent Noninferior to ZES at 3 Years: ReCre8

News Conference News CRT 2021

Polymer-Free Stent Noninferior to ZES at 3 Years: ReCre8

Yael L. Maxwell

March 18, 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

March 16, 2021

Low Mortality and Stroke Rates With BASILICA Pre-TAVI, Registry Shows

News Conference News CRT 2021

Low Mortality and Stroke Rates With BASILICA Pre-TAVI, Registry Shows

Michael O'Riordan

March 09, 2021

As Paclitaxelgate Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice

News Conference News VIVA 2020

As ‘Paclitaxelgate’ Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice

November 27, 2020

No Angina? No Benefit to PCI Pre-TAVR: ACTIVATION

News Conference News PCR London Valves 2020

No Angina? No Benefit to PCI Pre-TAVR: ACTIVATION

November 26, 2020

CTA Doesn’t Add Value in At-Risk Patients Thought to Have ACS

News Conference News AHA 2020

CTA Doesn’t Add Value in At-Risk Patients Thought to Have ACS

November 20, 2020

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

News Conference News

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

November 19, 2020

Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT

News Conference News AHA 2020

Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT

November 15, 2020

Clopidogrel Should Remain Antiplatelet of Choice in Elective PCI: ALPHEUS

News Conference News AHA 2020

Clopidogrel Should Remain Antiplatelet of Choice in Elective PCI: ALPHEUS

Michael O'Riordan

November 14, 2020

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

News Conference News VIVA 2020

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

November 11, 2020

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

News Conference News VIVA 2020

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

November 09, 2020

Robotic PCI Can Protect Cath Lab Staff From COVID-19, Small Study Suggests

News Conference News TCT 2020

Robotic PCI Can Protect Cath Lab Staff From COVID-19, Small Study Suggests

October 22, 2020

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

News Conference News TCT 2020

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

October 22, 2020

While Rare, Surgical Removal of TAVR Carries Risks: Global EXPLANT-TAVR Registry

News Conference News TCT 2020

While Rare, Surgical Removal of TAVR Carries Risks: Global EXPLANT-TAVR Registry

October 21, 2020

Direct Temsirolimus Delivery Shows Promise in BTK: Phase II Study

News Conference News TCT 2020

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

October 18, 2020

Fewer Events and Symptoms With iFR-Optimized PCI, Suggests DEFINE-PCI Trial

News Conference News TCT 2020

Fewer Events and Symptoms With iFR-Optimized PCI, Suggests DEFINE-PCI Trial

Michael O'Riordan

October 17, 2020

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

News Conference News TCT 2020

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

October 17, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.